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Background. We sought to develop diagnostic test guidance deﬁnitions for pediatric enteric infections to facilitate the in-
terpretation of positive test results in the era of multianalyte molecular diagnostic test platforms. Methods. We employed
a systematic, two-phase, modiﬁed Delphi consensus process consisting of three web-based surveys and an expert panel face-to-
face meeting. In phase 1, we surveyed an advisory panel of North American experts to select pathogens requiring diagnostic test
guidance deﬁnition development. In phase 2, we convened a 14-member expert panel to develop, reﬁne, and select the ﬁnal
deﬁnitions through two web-based questionnaires interspersed with a face-to-face meeting. Both questionnaires asked panelists to
rate the degree to which they agreed that if the deﬁnition is met the pathogen is likely to be causative of clinical illness. Results. )e
advisory panel survey identiﬁed 19 pathogens requiring deﬁnitions. In the expert panel premeeting survey, 13 of the 19 deﬁnitions
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evaluated were rated as being highly likely (“agree” or “strongly agree”) to be responsible for acute gastroenteritis symptoms by≥67% of respondent panel members. )e deﬁnitions for the remaining six pathogens (Aeromonas, Clostridium diﬃcile,
Edwardsiella, nonenteric adenovirus, astrovirus, and Entamoeba histolytica) were indeterminate. After the expert panel meeting,
only two of the modiﬁed deﬁnitions, C. diﬃcile and E. histolytica/dispar, failed to achieve the a priori speciﬁed threshold of ≥67%
agreement. Conclusions.We developed diagnostic test guidance deﬁnitions to assist healthcare providers for 17 enteric pathogens.
We identiﬁed two pathogens that require further research and deﬁnition development.
1. Introduction
Diarrheal disease is the second leading cause of child
mortality worldwide [1, 2] and is among the most common
causes of illness globally, with over 4 billion episodes oc-
curring annually [3–5]. In the United States, there are 178.8
million episodes of diarrhea contributing to 473,832 hos-
pitalizations each year [6]. Infection by a variety of gas-
trointestinal pathogens, including parasites, bacteria, and
viruses, can cause vomiting and diarrhea that typiﬁes acute
gastroenteritis. Multiple diagnostic testing methods are
available to identify enteric pathogens including traditional
culture techniques for enteric bacteria, direct microscopy for
parasites, enzyme immunoassay (EIA) for select enteric
viruses, bacterial toxins and some parasites, and molecular
methods for speciﬁc targets. Despite the availability of
multiple modalities to identify enteric pathogens, the eti-
ology often remains unidentiﬁed. However, recent practice
changes including the collection of rectal swabs rather than
stool specimens [7–9] to increase specimen acquisition rates,
and the increasing use of molecular methods, especially
syndromic panels which detect multiple pathogens simul-
taneously [10–12] have signiﬁcantly increased the detection
rates of enteric pathogens in symptomatic individuals [13].
Existing guidelines on the diagnosis [14] and manage-
ment [15] of enteric infectious diseases do not adequately
consider the implications of recent advances in sample
collection or molecular diagnostic techniques. For example,
recently published adult guidelines by the American College
of Gastroenterology suggest that the best applicability
for molecular diagnostic tests is for the clinician in practice,
but do not provide guidance on how clinicians should in-
terpret the results of such testing [16]. )e implementation
of commercial multiplex gastrointestinal pathogen panels
presents practical challenges to healthcare providers in
assessing the clinical relevance of positive results and to
public health oﬃcials who are responsible for surveillance
and follow-up of reportable infectious agents. Positive re-
sults generated by molecular assays cannot distinguish be-
tween asymptomatic carriage, subclinical infection, active
disease, resolved disease, or the presence of target nucleic
acids liberated by nonpathogens [16]. High rates of enteric
pathogen detection have been reported in asymptomatic
children [17]. Commercially available multianalyte panels
also identify organisms that were not previously routinely
tested for such as non-O157 Shiga toxin-producing
Escherichia coli (STEC). )ese challenges highlight the
need for the use of standardized deﬁnitions to guide the
interpretation of multiplex polymerase chain reaction (PCR)
results by clinicians who often have limited knowledge of
laboratory testing procedures. While deﬁnitions do exist for
some enteric pathogens in the context of public health and
outbreak management, no speciﬁc deﬁnitions exist to guide
interpretation and management by healthcare providers.
)e latter are important because accurate diagnosis by front-
line clinicians is crucial to identify those patients who would
beneﬁt from antimicrobial therapy and those where un-
necessary antibiotics may cause harm [15].
Given the existing knowledge gap, and the paucity of
high-quality evidence supporting the clinical interpretation
of multianalyte molecular diagnostic test platforms, we
conducted a modiﬁed Delphi consensus process to develop
provisional diagnostic test guidance deﬁnitions for pediatric
enteric infections to guide the interpretation, by clinicians,
of positive diagnostic test results. )e goal was to provide
guidance for clinicians providing care to children up to 18
years of age with symptoms of acute gastroenteritis deﬁned
as a decrease in stool consistency and/or by the presence of
three or more episodes of stool or vomiting in a 24-hour
period with duration of symptoms of less than seven days
[18, 19].
2. Materials and Methods
)e approach consisted of a systematic, two-phase, modiﬁed
Delphi consensus methodology with three web-based sur-
veys and an expert panel face-to-face meeting [20]. Ethics
approval for this study was obtained by the Conjoint Health
Research Ethics Board of the University of Calgary.
2.1. Phase 1: Selection of Pathogens Requiring Diagnostic Test
Guidance Deﬁnition Development. An advisory panel was
convened to (1) identify pathogens that require further
deﬁnition development and (2) select diagnostic tests
including culture, electron microscopy (EM), PCR and
EIA, and specimen types (i.e., stool, oral, and rectal swabs
[21]), which, if positive, would fulﬁll the deﬁnition for each
agent. )e advisory panel consisted of pediatricians, pe-
diatric emergency medicine and infectious diseases phy-
sicians, gastroenterologists, medical microbiologists, and
experts in virology and laboratory medicine. Selection
criteria for panel members included interest or expertise in
pediatric enteric infections as demonstrated by publica-
tions in the ﬁeld, experience in infectious diseases, geo-
graphic and practice diversity, and balance between
individuals with clinical and laboratory expertise. Can-
didate panel members received a written invitation to
participate that contained a description of study goals,
responsibilities, and timelines.
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Candidate advisory panel members received a web-based
surveymanaged in REDCap [22] in which they were asked to
(1) rate the degree to which they agreed, on a scale of 1-
disagree strongly to 5-agree strongly, that a positive result
for each of pathogen/diagnostic test/sample collection
methods is causative of the child’s symptoms. It was de-
termined a priori that any pathogen which was unanimously
rated as “agree strongly” for all diagnostic test/sample col-
lection modalities would be removed from further consid-
eration as unanimous agreement would indicate that further
deﬁnition is not required. All other pathogens were retained
for further deﬁnition development. Free text comments were
permitted.
We assessed a list of 19 agents (11 bacteria, 5 viruses, and
3 parasites) that were included in the diagnostic testing
panels being evaluated as part of the APPETITE (Alberta
Provincial Pediatric EnTeric Infection TEam) project [7].
APPETITE is a provincial initiative designed to compre-
hensively understand the epidemiology of acute pediatric
enteric infections employing rectal swabs and stool samples
and a comprehensive diagnostic testing approach.
2.2. Phase 2: Development of Diagnostic Test Guidance
Deﬁnitions. )e study team identiﬁed existing deﬁnitions
for each pathogen retained from phase 1 based on a review of
Canada’s provincial public health case deﬁnitions. For
pathogens with no existing syndromic-based deﬁnitions, the
study team developed candidate deﬁnitions based on the
results of the advisory panel survey in phase 1.
2.3.ExpertPanel. We convened an expert panel to reﬁne and
select the ﬁnal deﬁnitions. )e expert panel consisted of
individuals trained in pediatrics, infectious diseases, public
health, gastroenterology, medical microbiology, virology,
and laboratory medicine. Panelists were selected by study
investigators from the initial advisory panel and based on
recommendations from APPETITE’s International Scien-
tiﬁc Advisory Committees [7]. Selection criteria included
interest or expertise in pediatric enteric infections, clinical
decision making experience, geographic and practice di-
versity, and publications.
A description of research project goals, a summary of the
advisory panel survey results, and the existing and newly
developed evidence-based deﬁnitions were sent to expert
panel members. A modiﬁed Delphi technique consisting of
two rounds of anonymous questionnaires, and a face-to-face
meeting was used to generate ﬁnal study deﬁnitions.
2.3.1. Expert Panel Survey 1. )e ﬁrst web-based ques-
tionnaire asked panelists to rate the degree to which they
agreed that if the deﬁnition is met, in a child with vomiting
and/or diarrhea, the pathogen is likely to be the cause of the
illness. All deﬁnitions were speciﬁed to be in the context of
(1) clinical illness with acute gastroenteritis deﬁned as
a decrease in stool consistency and/or by the presence of
three or more episodes of loose stool or vomiting in a 24-
hour period with a duration of symptoms less than seven
days and (2) a positive laboratory diagnostic test for a single
pathogen (i.e., no codetection). Specimens considered in-
cluded stool as well as oral [23] and rectal swabs. Panelists
were asked to rate each deﬁnition employing a Likert scale
ranging from 1 (strongly disagree) to 5 (strongly agree). An
option was provided to suggest additional or alternate
deﬁnitions.
2.3.2. Face-to-Face Meeting. After completion of the ﬁrst
survey, an expert panel face-to-face meeting was convened
in Edmonton, Alberta, on March 4, 2016. At the meeting,
panelists reviewed anonymized ratings of all the deﬁnitions.
It was determined a priori that unanimously highly rated
deﬁnitions (i.e., those rated “agree” or “agree strongly” by all
respondents) would be retained, and unanimously low rated
deﬁnitions (i.e., rated “disagree strongly” or “disagree” by all
respondents) would be discarded and not discussed further.
Panelists were asked to reﬁne highly scored deﬁnitions
(i.e., ≥67% of panelists rated “agree” or “strongly agree”) and
to discuss the remaining deﬁnitions.
2.3.3. Expert Panel Survey 2. After the face-to-face meeting,
expert panel members received a ﬁnal survey requesting that
they independently re-rate each of the reﬁned deﬁnition
using the same rating scale. Deﬁnitions rated “agree” or
“strongly agree” by ≥67% of panelists were retained in the
ﬁnal list of deﬁnitions. )e threshold for retention was
determined a priori by the expert panel at the outset of the
expert panel meeting and has been previously used with such
methods [24]. Pathogens for which a consensus deﬁnition
could not be reached (i.e., further research required) were
identiﬁed.
3. Results
3.1. Phase 1. Modiﬁed Delphi consensus process used to
develop diagnostic test guidance deﬁnitions for pediatric
enteric diseases is shown in Figure 1.
)e advisory panel web-based survey was initially dis-
tributed to 88 individuals on March 26, 2015, with two
follow-up e-mail reminders. )irty-seven of 88 invited ex-
perts (42%) completed the advisory panel survey. )e ma-
jority (89%; 33/37) of respondents were ≥40 years of age and
practiced in Canada (76%; 28/37); the remaining 24% (9/37)
were from the United States. )e majority of the Canadian
participants were from Alberta (52%; 14/27). Other prov-
inces and territories represented included British Columbia,
Northwest Territories, Nova Scotia, Ontario, and Quebec.
Advisory panel participants included individuals with ex-
pertise in medical microbiology, pediatric infectious disease,
pediatric emergency medicine, community and public
health, and laboratory medicine (see Supplemental Table 1).
Respondents were similar to nonrespondents with respect to
specialty and geographic location.
No pathogen-test method had unanimous agreement
(i.e., rated “strongly agree” by all) in terms of assigning
causality of symptoms in a child with acute gastroenteritis
(Table 1). Consequently, all 19 pathogens were considered to
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require deﬁnition development. For bacterial pathogens, the
median proportion agreeing with causality (i.e., rated
“agree” or “strongly agree”) was higher for stool culture
(90%) compared with stool PCR (83%) and oral swab PCR
(30%). )e bacterial pathogen with the lowest percent en-
dorsement by both culture (40%; 95% CI: 23, 59) and PCR
(30%; 95% CI: 15, 50) was Edwardsiella. Aeromonas and
Clostridium diﬃcile also generated <50% agreement as to
likelihood of being etiologic when identiﬁed. Viral patho-
gens identiﬁed by stool PCR had high levels of agreement as
likely being the cause of the symptoms (range: 75–97%) with
the exception of general adenovirus which was associated as
etiologic by only 51% of respondents (95% CI: 34%, 68%).
All positive results on stool evaluated for parasites were
endorsed by over 50% of study participants.
3.2. Phase 2
3.2.1. Expert Panel: Premeeting Survey. Fourteen of 17 (82%)
individuals invited to participate in the in-person expert panel
process completed a premeeting deﬁnition survey (Supple-
mental Table 2). )e survey was distributed on January 22,
2016, with an e-mail reminder one week later (Table 2).
)irteen of the 19 deﬁnitions evaluated were rated as being
highly likely (“agree” or “strongly agree”) to be responsible for
acute gastroenteritis symptoms by ≥67% of respondent panel
members. )e deﬁnitions for the remaining six agents
(Aeromonas, C. diﬃcile, Edwardsiella, nonenteric adenovirus,
astrovirus, and Entamoeba histolytica) were indeterminate.
)e lowest rated bacterial pathogen was C. diﬃcile (36%; 95%
CI: 14, 64) while Escherichia coli O157 :H7 was the only
pathogen classiﬁed as etiologic by 100% of respondents.
Adenovirus was the lowest rated (36%; 95% CI: 14, 64) viral
pathogen while norovirus was the only pathogen classiﬁed as
etiologic by 100% of respondents.
Table 1: Results from initial advisory panel survey reporting re-
spondents who rated “agree” or “strongly agree” that the patho-










Stool culture 43 26, 62
Stool PCR 37 21, 56
Oral swab PCR 13 4, 32
Campylobacter
Stool culture 97 81, 100
Stool PCR 83 65, 94
Oral swab PCR 30 15, 50
Clostridium diﬃcile antigen
Stool EIA 50 32, 68
Stool PCR 47 29, 65
Oral swab PCR 17 6, 35
Edwardsiella
Stool culture 40 23, 59
Stool PCR 30 15, 50
Oral swab PCR 17 6, 35
Escherichia coli O157
Stool culture 97 81, 100
Stool PCR 87 68, 96
Oral swab PCR 37 21, 56
Enterotoxigenic Escherichia coli (ETEC)
Stool culture 90 73, 97
Stool PCR 84 66, 94
Oral swab PCR 29 15, 48
Salmonella spp.
Stool culture 81 62, 92
Stool PCR 77 57, 89
Oral swab PCR 20 8, 39
Shigella spp.
Stool culture 97 81, 100
Stool PCR 90 74, 97
Oral swab PCR 33 18, 53
Shiga toxin-producing Escherichia coli (STEC)
Stool culture 87 68, 96
Stool PCR 80 61, 92
Oral swab PCR 33 18, 53
Vibrio cholera
Stool culture 93 76, 99
Stool PCR 83 65, 94
Oral swab PCR 33 18, 53
Yersinia enterocolitica
Stool culture 93 76, 99
Stool PCR 83 65, 94
Oral swab PCR 33 18, 53
Viral pathogens
Adenovirus (any serotype)
Stool PCR 51 34, 68
Oral swab PCR 31 17, 49
Adenovirus 40/41
Stool PCR 81 63, 91
Oral swab PCR 54 37, 71
Astrovirus
Stool PCR 83 66, 93
Oral swab PCR 47 30, 65
Expert panel survey 1
13 highly rated deﬁnitions
6 indeterminate deﬁnitions
Face-to-face meeting
All case deﬁnitions reﬁned
Phase 1: selection of pathogens requiring case deﬁnitions
Advisory panel survey
19 pathogens identiﬁed
Phase 2: development of case deﬁnitions
Expert panel survey 2 
17 case deﬁnitions
2 pathogens requiring further case
deﬁnition development
Figure 1: Modiﬁed Delphi consensus process.
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3.2.2. Expert Panel: Meeting. Twelve of 14 (86%) expert
panel members convened at a meeting on March 5, 2016, in
Edmonton, Alberta. )e discussion focused on achieving
deﬁnitions which could obtain broad endorsement by ex-
perts. )e results of the advisory panel survey (Table 1) and
the ﬁrst expert panel survey (Table 2) were presented and
used to modify the deﬁnitions. )e deﬁnitions for all 19
pathogens were discussed and revised with the meeting
focused primarily on reviewing the six agents with in-
determinate ratings. Revisions included the speciﬁc wording
of both the deﬁnition and the agent. For example, the generic
term “nucleic acid test” (NAT) was adopted to replace more
speciﬁc terminology such as PCR. Yersinia pseudotubercu-
losis was removed from the deﬁnition for Yersinia enter-
ocolitica because the expert panel felt it is unclear if Yersinia
pseudotuberculosis causes GI illness. For viruses, adenovirus
(any serotype) was reworded to adenovirus (nontyped). For
parasites, Entamoeba histolytica was updated to Entamoeba
histolytica/dispar because, although dispar is not pathogenic,
the two agents cannot be diﬀerentiated using direct mi-
croscopy or by most antigen-detection tests [25–27]. )e
deﬁnitions that emerged from this process were then
recirculated via a ﬁnal survey to all attendees.
3.2.3. Expert Panel: Postmeeting Survey. All twelve experts
who attended the panel meeting completed the ﬁnal survey
which was distributed on March 21, 2016 (100% response
rate; Table 3). Eight of the ﬁnal deﬁnitions had a proportional
agreement of 100%. C. diﬃcile and E. histolytica/dispar did
not achieve the a priori speciﬁed threshold of ≥67%
agreement. Sixteen of the 19 (84%) modiﬁed deﬁnitions had
a higher proportion agreement than the deﬁnitions presented
in the expert panel premeeting survey.
4. Discussion
)is rigorous and systematic process provides expert
consensus-based diagnostic test guidance deﬁnitions for 17
organisms contained in gastroenteritis nonculture detection
panels. )ese deﬁnitions provide guidance to healthcare
providers on the interpretation of positive diagnostic test
results in the era of multianalyte molecular diagnostics. We
identiﬁed two pathogens (C. diﬃcile and E. histolytica/dispar)
for which further research and deﬁnition development is
required.
Our deﬁnition work is important as multianalyte enteric
pathogen detection approaches are rapidly being adopted
across North America. Many healthcare providers may have
a limited understanding that these molecular techniques
detect nucleic acids of targeted organisms but do not dif-
ferentiate nonviable organisms or free DNA/RNA from
viable pathogens. Positive results generated by molecular
assays do not deﬁnitively distinguish between asymptomatic
carriage, subclinical infection, active disease, resolved dis-
ease, or the presence of nucleic acids originating in non-
pathogens. )ey also do not provide deﬁnitive information
about virulence potential, and asymptomatic children have
been found to have high rates of enteric pathogen identi-
ﬁcation [17, 28].
A positive C. diﬃcile test represents the classic challenge
clinicians face in multianalyte arrays as its presence may
represent colonization and not pathogenic infection, par-
ticularly in infancy [11, 13, 28, 29]. Manymultianalyte panels
also identify organisms that were not previously routinely
sought, such as enteroaggregative E. coli (EAEC), and en-
teropathogenic E. coli (EPEC). )e latter two bacteria have
been identiﬁed in 84% of mixed infections, raising questions
about the clinical signiﬁcance of their identiﬁcation and the
validity of the deﬁnitions employed [13]. As such, the
deﬁnitions developed in our study can serve as a starting
point for clinicians interpreting the results of multianalyte
arrays.
Our study also reﬂects current understanding of the use
of oral swab NAT for the diagnosis of bacterial and viral
enteric organisms. )e paucity of evidence regarding the
utility of oral swabs is reﬂected in the poor ratings for the use
of oral swabs in our advisory panel survey and has sub-
sequently been supported by a recent study [21]. As a result,
oral swabs are not included in any of the deﬁnitions with the
exception of norovirus for which there is some evidence of
clinical utility [23, 30].
We were unable to develop consensus-based diagnostic
test guidance deﬁnitions for two pathogens,C. diﬃcile and E.
histolytica/dispar. )is is not surprising given the challenges
surrounding the accurate diagnosis of C. diﬃcile. Among
healthy adults, asymptomatic C. diﬃcile colonization
prevalence varies between 0 [31] and 7% [32], and it is even
higher in healthy newborns and infants [33]. )e prevalence









Stool PCR 94 80, 99
Oral swab PCR 60 42, 76
Rotavirus
Stool PCR 97 84, 100
Oral swab PCR 43 28, 60
Sapovirus
Stool PCR 75 57, 87
Oral swab PCR 40 24, 58
Parasitic pathogens
Cryptosporidium spp.
Stool ova and parasite 86 66, 95
Stool PCR 68 48, 83
Stool EIA 64 44, 81
Entamoeba histolytica
Stool ova and parasite 57 37, 75
Stool culture 68 48, 83
Stool PCR 61 41, 78
Stool EIA 75 55, 89
Giardia lamblia
Stool ova and parasite 86 66, 95
Stool PCR 68 48, 83
Stool EIA 75 55, 89
EIA, enzyme immunoassay; PCR, polymerase chain reaction. Stool culture,
ova and parasite, and EIA: bulk stool and/or rectal swab.
Canadian Journal of Infectious Diseases and Medical Microbiology 5
the ﬁrst month of life to approximately 15% by one year of
age [34]. However, 10–20% of older infants continue to
asymptomatically carry toxigenic organisms and the asso-
ciated toxin genes, and in many asymptomatic children, the
toxins are well expressed [28, 35]. In addition, there is
limited evidence on the duration of the colonized state, the
risk factors related to transmission, and the mechanisms
underlying progression from colonization to disease [33].
)e lack of a standardized deﬁnition for asymptomatic
colonization, or carriage, makes the interpretation of test
ﬁndings, and the development of a diagnostic test guidance
deﬁnition, diﬃcult. Further research is required to develop
Table 2: Expert panel survey, prior to in-person meeting, where attendees rated the degree to which they agreed that if the provided
deﬁnition was met, in a child with vomiting and/or diarrhea, the pathogen is highly likely to be causative of clinical illness.








Bacterial pathogens, N (%)












A positive toxin A or B assay for
Clostridium diﬃcile from a stool
specimen via PCR for toxin A/B










Isolation of Escherichia coli O157 :H7
from a stool specimen via culture, EIA,
or PCR





Isolation of Shiga toxin-producing
Escherichia coli (non-O157 : H7) from
a stool specimen via culture, EIA, or
PCR
0 0 1/14 (7%) 8/14(57%)
5/14
(36%) 93













Isolation of cholera toxin-producing
Vibrio cholerae serotype O1 or O139
from a stool specimen via culture or
PCR





Isolation of Yersinia enterocolitica or
Yersinia pseudotuberculosis from a stool
specimen via culture or PCR





Viral pathogens, N (%)
Rotavirus
Isolation of rotavirus from stool
specimen by EM, EIA, latex
agglutination, or PCR





Isolation of adenovirus in a stool




















Parasitic pathogens, N (%)
Cryptosporidium
Isolation of Cryptosporidium from
a stool specimen via microscopy, EIA,
or PCR







Detection of Entamoeba histolytica














EIA, enzyme immunoassay; PCR, polymerase chain reaction. Stool specimen includes bulk stool and/or rectal swab. All deﬁnitions are in the context of
a single-positive pathogen.
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Table 3: Deﬁnitions that emerged from in-person meeting and subsequently circulated for ﬁnal evaluation by the deﬁnition meeting
attendees.









from initial (1) and
second survey (2)
Bacterial pathogens, N (%)
Aeromonas
Detection of Aeromonas in











spp. from a stool specimen via
culture or NAT (e.g., PCR)
0 0 0 8/12(67%)
4/12
(33%) 100





diﬃcile toxin A or B from
a stool specimen via NAT (e.






Stool EIA, oral swab
PCR (1); none (2)







Stool PCR, oral swab




Detection of Escherichia coli
O157 :H7 from a stool
specimen via culture, EIA or
NAT (e.g., PCR)
0 0 0 5/12(42%)
7/12
(58%) 100






Detection of shiga toxin-
producing Escherichia coli
(non-O157 :H7) from a stool
specimen via culture, EIA or
NAT (e.g., PCR)
0 0 0 7/12(58%)
5/12
(42%) 100
Oral swab PCR (1);
none (2)
Salmonella
Detection of Salmonella spp.
from a stool specimen via
culture or NAT (e.g., PCR)
0 0 0 7/12(58%)
5/12
(42%) 100
Oral swab PCR (1);
none (2)
Shigella
Detection of Shigella spp. from
a stool specimen via culture or
NAT (e.g., PCR)
0 0 0 6/12(50%)
6/12
(50%) 100






Detection of Vibrio cholerae
serotype O1 or O139 from
a stool specimen via culture or
NAT (e.g., PCR)
0 0 1/12 (8%) 5/12(42%)
6/12
(50%) 92





enterocolitica from a stool
specimen via culture or NAT
(e.g., PCR)
0 0 0 6/12(50%)
6/12
(50%) 100
Oral swab PCR (1);
none (2)




(nontyped) in a stool














Detection of adenovirus 40/41
in a stool specimen via EIA or
NAT (e.g., PCR)
0 0 1/12 (8%) 6/12(50%)
5/12
(42%) 92
Oral swab PCR (1);
none (2)
Astrovirus
Detection of astrovirus in
a stool specimen via NAT (e.
g., PCR)





Oral swab PCR (1);
none (2)
Norovirus
Detection of norovirus from
a stool specimen or ORAL
SWAB via NAT (e.g., PCR)
0 0 0 8/12(67%)
4/12
(33%) 100 None (1 and 2)
Rotavirus
Detection of rotavirus from
a stool specimen by EM, EIA
or NAT (e.g., PCR)
0 0 0 4/12(33%)
8/12
(67%) 100




Detection of sapovirus in
a stool specimen via NAT (e.
g., PCR)
0 0 1/12 (8%) 8/12(67%)
3/12
(25%) 92
Oral swab PCR (1);
none (2)
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an evidence based, standardized deﬁnition for C. diﬃcile
disease, and equally importantly, colonization.
In the developing world, E. histolytica is a common cause
of protozoan morbidity and mortality [36]. However, in-
fection is uncommon in North America, and occurs pri-
marily in immigrants and travelers from developing
countries [37]. Nonetheless, asymptomatic colonization is
common, occurring in up to 4% of individuals in high-risk
areas [38], such as California, and it occurs with both E.
histolytica and the nonpathogenic E. dispar. Colonization
with the morphologically identical parasite E. dispar is three
times more common in developing countries and at least ten
times more common in developed nations [37]. Routine
diagnostic tests such as direct microscopy cannot diﬀer-
entiate between E. histolytica and E. dispar based on mor-
phologic criteria, so most laboratory reports indicate E.
histolytica/dispar [14]. )e relatively low prevalence in
North America, combined with the high colonization rates
with both the pathogenic, and nonpathogenic form, and the
diﬃculty in diﬀerentiating the two, likely account for the
lack of consensus for a diagnostic test guidance deﬁnition. It
should also be noted that the panel consisted of individuals
who have largely practiced in North America, where ame-
biasis is exceptionally rare in childhood. However, recently
published work on the most common causes of diarrhea
using molecular methods indicated that even in Asia and
Africa, the most common causes of diarrhea were Shigella,
rotavirus, adenovirus 40/41, heat-stable enterotoxin-
producing E. coli, Cryptosporidium, and Campylobacter,
which supports the broad-based utility of our clinical def-
initions [2].
A strength of this project is the use of a rigorous con-
sensus methodology consisting of multiple survey rounds
and a face-to-face meeting, which enabled dialogue [20].
Similar methods have been used to combine best evidence
and expert opinion in a number of clinical and research
settings [39, 40] including antimicrobial stewardship [41].
Both our advisory and expert panels had geographic rep-
resentation from throughout North America and including
a diversity of disciplines, thereby contributing to the utility,
credibility, and generalizability of our deﬁnitions. We had
representation from a broad spectrum of stakeholders in-
volved in the diagnosis and management of pediatric in-
fectious enteric diseases including front-line clinicians,
medical microbiologists, infectious disease specialists, and
public health experts. )e engagement of our expert panel,
with 86% of our expert panel participating in the face-to-face
meeting, and a 100% response rate on our ﬁnal survey, is
evidence of the relevance and importance of the topic and
the validity of the results. Nonetheless, our deﬁnitions can be
considered as a derivation set; future work should include
a validation with a distinct expert panel.
It should be noted that the deﬁnitions provided are only
applicable in the setting of a test that is positive for a single
pathogen. Clinicians should also be cognizant that in most
cases where the deﬁnitions provided are met, therapy re-
mains predominantly supportive and few of the enter-
opathogens included in Table 3 require antimicrobial
treatment, which can at times even be detrimental [42].
Although multiple pathogens are detected in ∼15% of stool
specimens in children with diarrhea [10], determining
guidelines for the interpretation of a positive test for more
than one pathogen was beyond the scope of this project. )e
guidance provided is also very general and does not in-
corporate themyriad of clinical scenarios that can occur.)e
deﬁnitions are not intended to replace expert opinion
(e.g., infectious disease specialist, medical microbiologist)
but rather are intended to assist clinicians in the context of
otherwise healthy children with typical clinical features and<7 days of symptoms. We also identiﬁed two agents, C.
diﬃcile and E. histolytica/dispar, for which further research
is required to develop accurate diagnostic test guidance
deﬁnitions. Prospective research currently underway [7] is
attempting to validate these deﬁnitions in the clinical setting
of pediatric enteric illness.
We also did not assess the conﬁdence in the individual
items included in each deﬁnition, nor the potential role of
quantitative molecular techniques [2]. )us, although the
deﬁnitions may include multiple diagnostic testing methods,
the test characteristics of each modality vary. While these
Table 3: Continued.









from initial (1) and
second survey (2)
Parasitic pathogens, N (%)
Cryptosporidium
Detection of Cryptosporidium
from a stool specimen via
microscopy, EIA or NAT (e.g.,
PCR)



















EIA (1); none (2)
Giardia
lamblia
Detection of Giardia lamblia
in a stool specimen via
microscopy or EIA





PCR (1); none (2)
EIA, enzyme immunoassay; EM, electron microscopy; NAT, nucleic acid test, PCR, polymerase chain reaction. Stool specimen includes bulk stool and/or
rectal swab. All deﬁnitions are in the context of a single-positive pathogen.
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deﬁnitions may lead clinicians to conclude that all diagnostic
tests are created equal, as diagnostic testing evolves and
progresses, less accurate tests are phased out and replaced by
superior diagnostic tests. It should also be noted that our
process did not include some of the diarrheagenic E. coli
strains (e.g., ETEC, EAEC, and EPEC) that are included in
some multianalyte tests while it did include some pathogens
not routinely identiﬁed by all laboratories (e.g., Edwardsiella).
)is likely stems from the fact that few clinicians and mi-
crobiologists have any signiﬁcant experience with the de-
tection of these enteric pathogens outside of research settings.
Currently, very few commercially available assays include all
these pathogen targets [43]. As experience is accumulated
with the detection of these pathogens in clinical laboratories,
it would certainly be useful to include them in a subsequent
evaluation. Finally, as we had to limit the number of study
participants, and their expert opinions may not reﬂect the
entire spectrum of expertise, our ﬁndings should not be
interpreted as the only perspective on this topic.
In conclusion, we report a rigorous, systematic, expert
consensus process that includes diagnostic test guidance
deﬁnitions for 17 enteric organisms.)ese deﬁnitions can be
employed by healthcare providers to interpret positive di-
agnostic test results in the era of multianalyte molecular
diagnostics as we await further clinical data, particularly with
respect to consideration of clinical settings and in-
terpretation of detection of more than one pathogen. We
also identiﬁed pathogens for which further deﬁnition de-
velopment is required.
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